Mereo BioPharma Investors Face April 6 Deadline in Lawsuits Over Failed Setrusumab Trials

Overview

• Class actions filed on behalf of investors who bought Mereo ADS between June 5, 2023 and December 26, 2025 cite alleged misstatements about Phase 3 programs.
• Law firms Faruqi & Faruqi, Berger Montague, and Wolf Haldenstein are recruiting investors to seek appointment as lead plaintiff.
• Complaints focus on claims that executives overstated the likelihood that the ORBIT and COSMIC trials would meet primary efficacy goals.
• Mereo disclosed on December 29, 2025 that both Phase 3 studies failed to reduce annualized clinical fracture rates, and the ADS price fell over 87% to $0.29.
• The company reported statistically significant bone mineral density gains on secondary endpoints and no new safety issues, but approval prospects were undermined by the primary misses.